No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
TWKS Thoughtworks
- 2.410
- -0.020-0.82%
Close Apr 23 16:00 ET
- 2.440
- +0.030+1.24%
Post 16:06 ET
778.01MMarket Cap-10954P/E (TTM)
2.470High2.375Low321.68KVolume2.420Open2.430Pre Close776.39KTurnover0.35%Turnover RatioLossP/E (Static)322.83MShares8.41052wk High1.01P/B221.55MFloat Cap2.19052wk Low--Dividend TTM91.93MShs Float34.430Historical High--Div YieldTTM3.91%Amplitude2.190Historical Low2.413Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
7 Stocks in Fin-tech and Payments Baird Analysts Like the Most
Expert Outlook: Thoughtworks Holding Through The Eyes Of 4 Analysts
Throughout the last three months, 4 analysts have evaluated Thoughtworks Holding (NASDAQ:TWKS), offering a diverse set of opinions from bullish to bearish.Summarizing their recent assessments, the tab
Thoughtworks Is Maintained at Neutral by Citigroup
Thoughtworks Is Maintained at Neutral by Citigroup
Express News | Citigroup Maintains Neutral on Thoughtworks Holding, Lowers Price Target to $2.5
Thoughtworks Holding Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/22/2024 5.93% Citigroup $2.75 → $2.5 Maintains Neutral 03/11/2024 16.53% Citigroup $5 → $2.75 Maintains
Express News | Thoughtworks Holding Inc : Citigroup Cuts Target Price to $2.5 From $2.75
Comments
Thoughtworks Holding's low P/S ratio is likely due to poor revenue performance and expectations of this trend continuing. The company's inferior revenue forecasts compared to the industry may contribute to the low P/S ratio, suggesting the share price may not rise significantly soon.
Little Excitement Around Thoughtworks Holding, Inc.'s (NASDAQ:TWKS) Revenues As Shares Take 35% Pounding
ColumnsBiotechnology Stocks Climbing on Earnings and Test Results: What to Watch
$Viking Therapeutics (VKTX.US)$skyrocketed 77% after positive drug trial news Tuesday, leading to what proved to be a strong morning for pharmaceutical stocks.
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...
6
Thoughtworks Holding's downward trend in ROCE and the continued usage of the same amount of capital signify a potentially mature business showing signs of decline. Unless there's a shift in these metrics, it might be wise to consider investing elsewhere.
2
Insiders' purchase of shares above current prices signifies optimism for the stock's value and an alignment with shareholder interests. Despite no insider transactions in the last three months, Thoughtworks Holding insiders seem undeterred about the company's future.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg